One Equity Partners exits InfuCare Rx investment through strategic buyback
By HME News Staff
Updated 11:25 AM CST, Thu December 18, 2025
FAIRFIELD, N.J. – One Equity Partners, a middle market private equity firm, has exited its investment in InfuCare Rx, Inc. through a strategic founder-led equity buyback. Financial terms of the private transaction were not disclosed. OEP says InfuCare Rx, founded in 2014, has become one of the nation’s largest privately held independent providers of specialty infusion therapies at home, as well as alternate sites of care. “When we first invested in InfuCare in early 2022, the business represented a compelling opportunity in the home infusion market, as health care was continuing to shift to the home and demographic trends were driving greater demand for chronic condition management,” said Inna Etinberg, partner at One Equity Partners. “Working closely with management, we implemented initiatives that strengthened InfuCare’s revenue cycle and enhanced operational efficiency, driving meaningful growth and value creation.” OEP also supported InfuCare’s acquisition of Florida-based Health First Infusion, enabling the expansion into the Florida market with a brick-and-mortar pharmacy presence.
Comments